Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes
Figure 5
Levels of apoAII-ATQ/AT, apoAII-ATQ, and apoAII-AT in the PDAC patients according to MPDD and PPV after CRT. (a) Comparison of distribution of apoAII-ATQ/AT, apoAII-ATQ, and apoAII-AT between the patients with small MPDD and those with large MPDD after CRT. The 44 PDAC patients were divided into small- or large-MPDD groups at the median level of MPDD (3.65 mm) after CRT. (b) Comparison of distribution of apoAII-ATQ/AT, apoAII-ATQ, and apoAII-AT between the patients with large PPV and those with small PPV after CRT. The 44 PDAC patients were divided into small- or large-PPV groups at the median level of PPV (29.5 ml) after CRT. PDAC: pancreatic ductal adenocarcinoma, MPDD: main pancreatic duct diameter, PPV: pancreatic parenchymal volume excluding tumor volume, and CRT: chemoradiotherapy.